Japan's Takeda Pharmaceutical is buying the U.K.'s Paradigm Therapeutics, a small development partner which has been helping Takeda identify drug targets with genetically altered animals. No terms were disclosed. Paradigm has already been working with Takeda on identifying experimental therapies for central nervous system diseases. Paradigm has a pipeline of targets for pain, central nervous system disorders, prostate and breast cancer, diabetes and obesity. Paradigm will be renamed Takeda Cambridge after the deal is completed. Paradigm was founded eight years ago by Cambridge researchers.
- check out the release on the acquisition
Related Articles:
Xenon licenses out pain drug to Takeda. Report
Takeda expands R&D budget, may look for buyout. Report